Literature DB >> 11423097

Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists.

T G Beach1, D G Walker, P E Potter, L I Sue, A Fisher.   

Abstract

Overproduction of the peptide amyloid beta (A beta) is a critical event in Alzheimer's disease (AD). Systemic administration of 3 M1-selective muscarinic agonists, AF102B, AF150S and AF267B, decreased cerebrospinal fluid (CSF) A beta concentrations; levels of CSF secreted beta-APP were not significantly altered. Rabbits treated for 5 days with s.c. injections of each drug (2 mg/kg/day) had levels of CSF A beta which were between 55 and 71% of control for A beta 1-40 and between 59 and 84% of control for A beta 1--42.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423097     DOI: 10.1016/s0006-8993(01)02484-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

3.  Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo.

Authors:  Albert A Davis; Jason J Fritz; Jürgen Wess; James J Lah; Allan I Levey
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

Review 4.  Wnt signaling: role in Alzheimer disease and schizophrenia.

Authors:  Nibaldo C Inestrosa; Carla Montecinos-Oliva; Marco Fuenzalida
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-18       Impact factor: 4.147

5.  Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.

Authors:  Rodrigo Medeiros; Masashi Kitazawa; Antonella Caccamo; David Baglietto-Vargas; Tatiana Estrada-Hernandez; David H Cribbs; Avraham Fisher; Frank M LaFerla
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

6.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.

Authors:  Pamela E Potter; Paula K Rauschkolb; Yoga Pandya; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2011-05-01       Impact factor: 17.088

Review 7.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun

Review 8.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

9.  In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors.

Authors:  Patrizia De Sarno; Gautam N Bijur; Anna A Zmijewska; Xiaohua Li; Richard S Jope
Journal:  Neurobiol Aging       Date:  2005-04-26       Impact factor: 4.673

10.  A novel mechanism of hippocampal LTD involving muscarinic receptor-triggered interactions between AMPARs, GRIP and liprin-alpha.

Authors:  Bryony A Dickinson; Jihoon Jo; Heon Seok; Gi Hoon Son; Daniel J Whitcomb; Ceri H Davies; Morgan Sheng; Graham L Collingridge; Kwangwook Cho
Journal:  Mol Brain       Date:  2009-06-17       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.